BioSpace News Archive

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on Wednesday, Feb. 16, 2022 to discuss the company’s fourth quarter and year-end 2021 financial results.

BioMarin Pharmaceutical Inc. announced that the Company will be presenting data in several presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders February 2-4.

Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, reported financial results for the fourth quarter and year ended December 31, 2021.

Outset Medical, Inc. today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, February 16, 2022.

Syros Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (MDS).

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 25, 2021.

Bio-Rad Laboratories, Inc. announced today that it will host an in-person investor day in New York City on Friday, February 25, 2022, at 10:30 a.m. EST. A live webcast will also be available.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced the company will be participating in the 11th Annual SVB Leerink Global Healthcare Conference.

SomaLogic, Inc., a leader in AI-data driven proteomics technology, announced that the company will be participating in the following virtual investor conferences.

NRx Pharmaceuticals announced that it has closed its previously announced private placement priced at a premium to market under Nasdaq rules of 7,824,727 shares of its common stock and unregistered preferred investment options to purchase up to an aggregate of 7,824,727 shares of common stock.